A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

Carcinoma, Hepatocellular Clinical Trial

— AMETHISTA  

Official title:

A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04487067
• Other study ID #: ML42243
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: August 25, 2020
• Est. completion date: August 13, 2024

Study information

• Verified date: May 2024
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase IIIb, one arm, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab + bevacizumab in patients with unresectable HCC who have received no prior systemic treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 152
• Est. completion date: August 13, 2024
• Est. primary completion date: August 13, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Unresectable HCC with diagnosis confirmed by histology, with a biopsy within 6 months from recruitment;

• Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies;

• No prior systemic therapy for HCC;

• At least one measurable untreated lesion;

• Patients who received prior local therapy are eligible provided the target lesion(s) have not been previously treated with local therapy or the target lesion(s) within the field of local therapy have subsequently progressed in accordance with RECIST version 1.1;

• ECOG Performance Status of 0 or 1 within 7 days prior to recruitment;

• Child-Pugh class A within 7 days prior to recruitment;

• Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) must be assessed. In case of varices at high risk of bleeding (corresponding to medium (F2) or large (F3) varices, or F1 varices with cherry red spots or red wale marking) prophylatic treatment per local standard of care must be adopted prior to enrollment. Patients who have undergone an EGD within 6 months of prior to initiation of study treatment do not need to repeat the procedure provided they had no varices at high risk of bleeding;

• Adequate hematologic and end-organ function

• Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade <= 1 prior to study entry, with the exception of alopecia

• Negative HIV test at screening with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count =200µL, and have an undetectable viral load;

• In patients with viral HCC, documented virology status of hepatitis, as confirmed by screening HBV and HCV serology test;

• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs.

• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.

Exclusion Criteria:

• History of leptomeningeal disease or brain metastases;

• Active or history of autoimmune disease or immune deficiency;

• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan;

• Known active tuberculosis;

• Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina;

• History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death;

• Prior allogeneic stem cell or solid organ transplantation;

• Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab and 6 months after the last dose of bevacizumab;

• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC;

• Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding;

• A prior bleeding event due to oesophageal and/or gastric varices within 6 months prior to initiation of study treatment;

• Clinically evident ascites;

• Co-infection of HBV and HCV;

• Co-infection with HBV and hepatitis D viral infection;

• Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases;

• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures;

• Clinically significant uncontrolled or symptomatic hypercalcemia;

• Inadequately controlled arterial hypertension;

• Significant vascular disease within 6 months prior to initiation of study treatment;

• History of haemoptysis;

• Evidence of bleeding diathesis or significant coagulopathy;

• History of gastrointestinal (GI) fistula, GI perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment;

• History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding prior to initiation of study treatment;

• Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses of large volume;

• Local therapy to liver within 28 days prior to initiation of study treatment or non-recovery from side effects of any such procedure.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Drug:
• Atezolizumab
Atezolizumab 1200 mg IV infusion q3w
• Bevacizumab
Bevacizumab 15 mg/kg IV Q3W

Locations

Country	Name	City	State
Italy	Ospedali Riuniti - Bergamo; Gastroenterologia	Bergamo	Lombardia
Italy	A.O. S. Orsola Malpighi; Ambulatorio Epatocarcinoma (Bolondi)	Bologna	Emilia-Romagna
Italy	A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia	Cagliari	Sardegna
Italy	A.O.U Careggi	Florence	Toscana
Italy	A.O. Universitaria S. Martino Di Genova	Genova	Liguria
Italy	Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia	Milano	Lombardia
Italy	Istituto Nazionale Dei Tumori; Dipartimento Chirurgia Generale - Unita' Trapianti Fegato	Milano	Lombardia
Italy	Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica	Napoli	Campania
Italy	Fondazione Pascale; U.O. Sperimentazioni Cliniche	Napoli	Campania
Italy	Ospedale del Mare; UOC di Oncologia	Napoli	Campania
Italy	IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II	Padova	Veneto
Italy	A.O.U. Policlinico Paolo Giaccone; Gastroenterologia ed Epatologia	Palermo	Sicilia
Italy	Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi	Palermo	Sicilia
Italy	Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2	Pisa	Toscana
Italy	Arcispedale Santa Maria Nuova; Oncologia	Reggio Emilia	Emilia-Romagna
Italy	Azienda Ospedaliera San Camillo Forlanini	Roma	Lazio
Italy	Policlinico Universitario Agostino Gemelli	Roma	Lazio
Italy	Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia	Rozzano	Lombardia
Italy	IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia	San Giovanni Rotondo	Puglia
Italy	Azienda Ospedaliera Ordine Mauriziano di Torino	Torino	Piemonte
Italy	Clinica Oncologica-Ospedali Riuniti Ancona	Torrette	Toscana

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Grade 3-5 NCI CTCAE v.5 Bleeding/Haemorrhage		Up to approximately 48 months
Secondary	Overall Survival (OS)	Overall survival (OS) is defined as the time from initiation of study treatment to death from any cause.	Up to approximately 48 months
Secondary	Number of Participants with Adverse Events	Number of participants with adverse events with severity determined according to NCI CTCAE v5.0.	Up to approximately 48 months
Secondary	Progression-Free Survival (PFS)	Progression-free survival (PFS) is defined as the time from initiation of study treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1	Up to approximately 48 months
Secondary	Objective Response Rate (ORR)	Objective response rate (ORR) is defined as a complete or partial response, as determined by the investigator according to RECIST v1.1	Up to approximately 48 months
Secondary	Time to Progression (TTP)	Time to progression (TTP) is defined as the time from initiation of study treatment to the first occurrence of disease progression, as determined by the investigator according to RECIST v1.1	Up to approximately 48 months
Secondary	Duration of Response (DOR)	Duration of response (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1	Up to approximately 48 months
Secondary	Post-Progression Survival (PPS)	Post-progression survival (PPS) is defined as the time from the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 to death from any cause.	Up to approximately 48 months
Secondary	Number of Participants Starting Second or Further Lines of Treatment		Up to approximately 48 months
Secondary	Number of Participants Reporting Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire	Participant self-reported symptomatic Adverse Events (AEs) using National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) questionnaire.	Up to approximately 48 months